- $1.57bn
- $1.11bn
- 48
- 25
- 54
- 37
Annual income statement for Disc Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.813 | 69.7 | 47.5 | 91.1 | 130 |
| Operating Profit | -0.813 | -69.7 | -47.5 | -91.1 | -130 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.813 | -71.9 | -46.8 | -76.3 | -109 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.813 | -71.9 | -46.8 | -76.4 | -109 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.813 | -71.9 | -46.8 | -76.4 | -109 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.813 | -71.9 | -46.8 | -76.4 | -109 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.53 | -17.6 | -2.69 | -3.42 | -3.96 |